Sai Life Sciences IPO GMP: Subscription BEGINS

Sai Life Sciences IPO GMP price today: Day 2 subscription today; check latest grey market premium
According to multiple websites that track grey market activities, Sai Life Sciences’s shares are commanding a premium of Rs 37. This translates into a GMP of 6.74 per cent
Sai Life Sciences IPO Day 2. Check key dates, price band, GMP, and review
Sai Life Sciences' IPO saw an 84% subscription rate on its first day. Institutional investors showed strong interest. The IPO aims to raise Rs 3,042 crore. The company plans to use the funds for debt repayment.
LIVE
Sai Life Sciences IPO Day 1 Live Updates: Issue subscribed 7% so far; check out GMP, anchor details & more
The proposed initial public offering includes a new issuance of equity shares amounting to ₹ 950 crore, along with an offer for sale (OFS) of 3.81 crore shares estimated to be worth ₹ 2,092 crore at the highest end of the price range, involving a promoter, investor shareholders, and other stakeholders.
Sai Life Sciences IPO fully subscribed on second day of bidding; Retail portion booked only 30%
The Qualified Institutional Buyers (QIBs) booked their quota 2.88 times even as the investors in other categories adopted a cautious approach. The portion reserved for retail investors was booked 30% whereas the Non-Institutional Investors (NIIs) booked 28% of the shares set aside for them.
Sai Life Sciences IPO Day 1: Issue subscribed 84% led by QIBs. Check GMP, other key details
Retail investors subscribed 8%, non-institutional investors 4%, while qualified institutional buyers made no bids yet for the Rs 3,042.62 crore IPO. The issue includes a fresh allotment of shares worth Rs 950 crore and an OFS of Rs 2,
LIVE
Sai Life Sciences IPO Day 1 Live Updates: Issue subscribed 84% on first day; QIB portion fully booked; check latest GMP
The proposed initial public offering includes a new issuance of equity shares amounting to ₹ 950 crore, along with an offer for sale (OFS) of 3.81 crore shares estimated to be worth ₹ 2,092 crore at the highest end of the price range, involving a promoter, investor shareholders, and other stakeholders.
Sai Life Sciences IPO fully subscribed on Day 2; QIBs drive demand
The unlisted shares of Sai Life Sciences were trading at Rs 586 apiece, reflecting a grey market premium (GMP) of Rs 37 or 6.74 per cent per share over the upper end of the IPO price band of Rs 549
Sai Life Sciences IPO subscribed 44% on the first day; Check price band, GMP, other details
Shares of Sai Life Sciences were trading at a premium of ₹28 in the grey market, at 4:30 PM on December 11, as per reports. The latest GMP for Sai Life Sciences IPO indicates an expected listing price of ₹577 per share with a potential listing gain of 5%.
Sai Life Sciences IPO subscribed 84%, QIB portion booked 2.62 times on Day 1; Check GMP, other details
Sai Life Sciences IPO opened for for public subscription on Wednesday, December 11 and will close on Friday, December 13. The public issue has received healthy booking from the QIB segment on Day 1.
‘To advance in life sciences we must be more ambitious and prioritise public investment in research’
Ireland’s economic success is due in no small part to the life sciences sector, but the challenge now is how to maintain a ...
MM&M19h
Pharma, life sciences execs ‘optimistic’ for 2025, eye regulatory concerns
Three-quarters of pharma and life sciences executives said they were optimistic for 2025, even though they expect some level ...
Dimension raises $500M second fund for investing at the intersection of tech and life sciences
Many VCs, particularly newer firms, readily admit that 2024 has been a challenging year for raising fresh capital. Dimension ...
Blackstone Eyes $5 Billion for Life Sciences Investments
Valuations of life sciences businesses declined in the wake of the global pandemic, but government stimulus and medical ...
Valsoft Strengthens Life Sciences Portfolio with the Acquisition of CRM Leader Exeevo
Valsoft Corporation Inc. (”Valsoft”), a Canadian company specializing in the acquisition and development of vertical market software businesses, has acquired Exeevo, a unified CRM solution for sales, ...
Tom Still: Life sciences ‘family tree’ in Wisconsin has big branch in Third Wave Technologies
Third Wave was an early example of why venture capital firms, almost entirely clustered on the East and West coasts in the early 1990s, came to discover Madison.
moneycontrol.com4h
Sai Life Sciences IPO gets subscribed 90% on Day 2 so far; QIB portion booked 2.62x
The public issue of Sai Life Sciences kept its positive momentum on Day 2 of its subscription as well and saw 90% subscription so far on December 12 with qualified institutional buyers or QIBs ...
Vishal Mega Mart vs Mobikwik vs Sai Life Sciences: Which is a better pick?
Vishal Mega Mart, Mobikwik, and Sai Life Sciences—launched, offering investors a variety of choices. Vishal Mega Mart is ...